Literature DB >> 33999579

Successful treatment of bullous pemphigoid with dupilumab: a case and brief review of the literature.

Maleck Saleh, Matthew Reedy1, Helen Torok, Joshua Weaver.   

Abstract

Bullous pemphigoid is an autoimmune skin disease that results in formation of pruritic blisters. Most cases are treated with a combination of systemic and topical corticosteroids as well as other immunomodulatory drugs. Dupilumab is a fully human monoclonal antibody that acts as an antagonist against IL4Ra traditionally used in the treatment of atopic dermatitis. We present an 80-year-old man with moderate to severe bullous pemphigoid successfully treated with dupilumab.

Entities:  

Year:  2021        PMID: 33999579

Source DB:  PubMed          Journal:  Dermatol Online J        ISSN: 1087-2108


  4 in total

Review 1.  Use of Dupilumab in Bullous Pemphigoid: Where Are We Now?

Authors:  Roberto Russo; Niccolò Capurro; Emanuele Cozzani; Aurora Parodi
Journal:  J Clin Med       Date:  2022-06-12       Impact factor: 4.964

2.  Commentary: Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Authors:  Si-Hang Wang; Ya-Gang Zuo
Journal:  Front Immunol       Date:  2021-11-23       Impact factor: 7.561

3.  Rituximab, Omalizumab, and Dupilumab Treatment Outcomes in Bullous Pemphigoid: A Systematic Review.

Authors:  Peng Cao; Wenjing Xu; Litao Zhang
Journal:  Front Immunol       Date:  2022-06-13       Impact factor: 8.786

4.  Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Authors:  Yihua Zhang; Qiuyun Xu; Lihong Chen; Jiawen Chen; Jing Zhang; Ying Zou; Ting Gong; Chao Ji
Journal:  Front Immunol       Date:  2021-10-14       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.